Idrx
IDRx was a clinical-stage biopharmaceutical company developing precision oncology therapeutics, with lead asset IDRX-42, a KIT inhibitor for gastrointestinal stromal tumor (GIST) patients, acquired by GSK for up to $1.15 billion in early 2025.
- Company typePrivate
- Founded2022
- HeadquartersCambridge, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Idrx does
IDRx, Inc. was a clinical-stage biopharmaceutical company founded in 2022 and headquartered in Plymouth, Massachusetts, focused on developing precision oncology therapeutics for genetically defined cancers. The company's scientific premise was that targeting specific genetic drivers of tumors — rather than relying on broad cytotoxic chemotherapy — could yield better efficacy and tolerability in defined patient populations. Its lead clinical asset, IDRX-42, is a small-molecule KIT inhibitor designed to address genetic drivers of KIT in gastrointestinal stromal tumors (GIST), an indication with persistent unmet need after front-line imatinib resistance. A second program, IDRX-73, advanced in parallel as part of a next-generation targeted therapeutics pipeline.
The company operated a classic clinical-stage biotech model: it was pre-revenue, did not commercialize any products, and derived no licensing or royalty income during its independent existence. Its go-to-market posture centered on scientific communication — peer-reviewed publications, oncology conference presentations, and investor relations — rather than field sales or distribution. Customer-facing activity was limited to engaging the scientific and clinical community, with the ultimate end users being GIST cancer patients whose tumors harbor targetable KIT mutations.
IDRx was capitalized through two venture rounds: a $122 million Series A in August 2022 led by Andreessen Horowitz (a16z) and Casdin Capital, and a $120 million Series B in August 2024 led by RA Capital Management, Commodore Capital, and Blackstone Multi-Asset Investing, totaling approximately $242 million raised. In January 2025 (closing February 2025), GSK plc agreed to acquire IDRx for up to $1.15 billion, including upfront and milestone payments, integrating IDRX-42 and the broader pipeline into GSK's oncology division for potential global development and commercialization.
Idrx firmographics
Firmographics- Name
- Idrx
- Legal name
- IDRx, Inc.
- Website
- https://idrx.com
- Company type
- Private
- Founded year
- 2022
- Operating status
- Acquired
- Headcount range
- 11–50 employees
- Short description
- IDRx was a clinical-stage biopharmaceutical company developing precision oncology therapeutics, with lead asset IDRX-42, a KIT inhibitor for gastrointestinal stromal tumor (GIST) patients, acquired by GSK for up to $1.15 billion in early 2025.
- Ownership category
- akta.pro rank
Where Idrx is headquartered
LocationHeadquarters
- HQ city
- Cambridge
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Idrx business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations
Revenue model
- Drug Development and Potential Commercialization: As a clinical-stage company, IDRx was pre-revenue, focused on developing drug candidates through clinical trials with the goal of achieving regulatory approval and commercializing treatments for cancer patients.
Go-to-market motion1 record
Marketing channels1 record
Idrx product offering
Product offeringCore offering
IDRx is a clinical-stage biopharmaceutical company developing precision oncology drugs, with a primary focus on selective KIT inhibitors for the treatment of gastrointestinal stromal tumors (GIST). The company's lead candidate IDRX-42 targets specific KIT mutations to address unmet needs in GIST therapy, supported by a pipeline that includes additional investigational compounds such as IDRX-73.
Product overview
IDRx is a precision cancer drug company developing a pipeline of targeted cancer therapeutics. The company's core products include IDRX-42, a KIT inhibitor for gastrointestinal stromal tumors (GIST), and IDRX-73, another compound in clinical development. Both drug candidates target specific genetic drivers of cancer. The company was acquired by GSK in 2025 as part of GSK's strategy to strengthen its oncology portfolio.
Differentiator
Problem solved
Functional benefit
Products and services
- IDRX-42 Selective KIT inhibitor drug candidate designed to treat gastrointestinal stromal tumors (GIST) by targeting specific KIT mutations; intended for oncologists and patients with GIST, particularly those resistant to existing therapies.
- IDRX-73 Additional investigational compound in IDRx's clinical-stage oncology pipeline, expanding the company's targeted cancer therapy portfolio beyond the lead IDRX-42 program.
Companies that use Idrx
Customer profileSegments1 record
Ideal customer profiles1 record
Idrx technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature2 records
Idrx partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- GSKcoreGSK acquired IDRx for up to $1.15 billion including upfront and milestone payments to strengthen its oncology pipeline with targeted cancer therapeutics including IDRX-42
Scale indicators3 records
Recent moves4 records
Expansion highlights3 records
Idrx competitors and assessment
Company assessmentBroad incumbents
- Eli Lilly: Lilly acquired both Deciphera Pharmaceuticals (Qinlock/GIST) and Theseus Pharmaceuticals (KIT inhibitors) in recent years, making it the most active large oncology acquirer of KIT/GIST assets. Lilly is a direct strategic peer to GSK for oncology pipeline M&A in this category.
- AstraZeneca: AstraZeneca operates a broad oncology franchise including targeted therapies across multiple tumor types. While not directly focused on GIST, it is a relevant broad incumbent peer for benchmarking precision oncology pipelines and strategic interest in KIT biology.
- Novartis: Novartis markets Gleevec (imatinib), the foundational KIT inhibitor for front-line GIST, and is the originator of the KIT-inhibitor class. While Novartis operates a much broader oncology portfolio, it is the historical standard-of-care competitor in the IDRx indication.
- Pfizer: Pfizer markets Sutent (sunitinib), an approved multi-kinase inhibitor used in 2L GIST, and operates a broad oncology franchise. Pfizer is a relevant comparable for strategic acquirers and commercial infrastructure post-approval.
Emerging players
- Revolution Medicines: Revolution Medicines is a clinical-stage precision oncology company developing targeted therapies against RAS/MAPK pathway and other oncogenic drivers. It is a peer for benchmarking clinical-stage precision oncology company-building, capital efficiency, and deal dynamics in oncology.
- Cogent Biosciences: Cogent is developing bezuclastinib, a KIT inhibitor in clinical trials for GIST and systemic mastocytosis. Cogent is an emerging direct competitor in the KIT/GIST space and a peer for benchmarking clinical strategy and deal economics.
- Theseus Pharmaceuticals: Theseus developed next-generation KIT inhibitors for GIST and was acquired by Lilly in 2024. Theseus is a closely comparable emerging precision oncology company targeting KIT-driven cancers with a similar strategic exit profile to IDRx.
- Mirati Therapeutics: Mirati developed precision oncology therapies (e.g., Krazati, a KRAS G12C inhibitor) and was acquired by Bristol Myers Squibb in 2024. Mirati is a closely comparable precision oncology company with a similar mid-cap acquisition exit profile to IDRx.
Direct peers
- Blueprint Medicines: Blueprint Medicines developed and commercializes Ayvakit (avapritinib), an approved KIT/PDGFRA inhibitor for GIST, and is a direct competitor to IDRX-42 in the KIT-mutant GIST space. Blueprint is the most directly comparable precision oncology company targeting the same biology and patient population.
- Deciphera Pharmaceuticals: Deciphera developed Qinlock (ripretinib), an approved KIT inhibitor for 4L GIST, and was acquired by Eli Lilly in 2021. Deciphera was a direct GIST competitor to IDRx and the IDRX-42 acquisition by GSK closely mirrors the Lilly–Deciphera strategic logic.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat2 records
Key risks5 records
Key highlights6 records
Customer concentration
Idrx financial estimates
Financial estimateRevenue estimate
Valuation estimate
Idrx leadership team
Management profileNumber of profiles
Profiles10 records
Idrx funding detail
Funding detailFunding overview
Funding rounds2 records
Investors9 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Idrx M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Idrx
What does Idrx do?
IDRx is a clinical-stage biopharmaceutical company developing precision oncology drugs, with a primary focus on selective KIT inhibitors for the treatment of gastrointestinal stromal tumors (GIST). The company's lead candidate IDRX-42 targets specific KIT mutations to address unmet needs in GIST therapy, supported by a pipeline that includes additional investigational compounds such as IDRX-73.
Is Idrx a public or private company?
Idrx is a private company. It is classified as corporate owned and is currently acquired.
When was Idrx founded?
Idrx was founded in 2022. It employs 11 to 50 people.
Where is Idrx based?
Idrx is headquartered in Cambridge, United States, in the North America region.
How does Idrx make money?
One revenue line is on record: drug Development and Potential Commercialization.
Who are Idrx's main competitors?
Broad incumbents on record are Eli Lilly, AstraZeneca, Novartis and Pfizer. Emerging players are Revolution Medicines, Cogent Biosciences, Theseus Pharmaceuticals and Mirati Therapeutics. Direct peers are Blueprint Medicines and Deciphera Pharmaceuticals.
Does Idrx have an API?
No public API is recorded for Idrx.